Trial Profile
Phase II Study of Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Novartis
- 12 Mar 2011 New trial record